VIA
ALXN

Virtus Investment Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Virtus Investment Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-940
Closed -$112K – 467
2017
Q4 		$112K Sell
940
-55
-6% -$6.7K 0.01% 464
2017
Q3 		$140K Sell
995
-105
-10% -$14.3K 0.01% 451
2017
Q2 		$134K Sell
1,100
-125
-10% -$14.5K 0.01% 457
2017
Q1 		$149K Buy
+1,225
New +$158K 0.01% 428
2016
Q4 		– Sell
-4,769
Closed -$584K – 542
2016
Q3 		$584K Buy
+4,769
New +$614K 0.04% 334

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtus Investment Advisers's ALXN Position: Q1 2018 in Review

Virtus Investment Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 940 shares — an estimated $112K sold.

Virtus Investment Advisers first reported a position in ALXN in Q3 2016 and held it in 5 quarters. The position peaked at $584K in Q3 2016. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Virtus Investment Advisers reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Virtus Investment Advisers sold 940 Alexion Pharmaceuticals shares in Q1 2018, an estimated $112K.
  • Virtus Investment Advisers first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • Virtus Investment Advisers's Alexion Pharmaceuticals position peaked at $584K in Q3 2016.
  • 596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Virtus Investment Advisers's 13F filing for Q1 2018, filed 15 May 2018.